TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today opinion article argues that a more vaccine-supportive Congress after the 2026 midterms may still have limited power to prevent changes to vaccine policy. The authors expect continued action from the executive branch and state-level disputes, but those forecasts are analysis, not confirmed future events.
Even if the 2026 midterms bring more vaccine-supportive lawmakers to Congress, that change may not prevent further federal and state challenges to vaccine policy, health policy writers Steven Grossman and Michael Miller argued in an October 20 MedPage Today opinion article. Their warning is a forecast, not a report of a new policy action: they say executive-branch decisions and state initiatives could continue to affect vaccine recommendations and access after the new Congress convenes on January 3, 2027.
Grossman and Miller say vaccine advocates made progress during 2026 by raising awareness of the potential effects of anti-vaccine policies and forming informal coalitions to respond to government actions. They cite opposition to changes involving the Advisory Committee on Immunization Practices (ACIP), federal vaccine advisory groups and respiratory vaccine recommendations, as well as state efforts to expand exemptions from school vaccination requirements.
The authors also point to a legal challenge over the reshaping of ACIP and reductions in its routine vaccine recommendations. They say many medical societies issued their own recommendations that largely reflected guidance from the committee before 2025. The article does not provide details about the lawsuit’s current status or establish that any court has resolved the dispute.
On the political outlook, the authors say vaccine advocates are likely to have greater representation in Congress next year. They describe Democratic control of the House as near certain and the Senate outcome as roughly even odds. Those are the authors’ assessments of the election outlook, not confirmed results. They argue that congressional support may be insufficient to constrain executive-branch actions, particularly if the administration resists oversight or legal limits.
Congress May Not Control Vaccine Policy
The debate matters because vaccine guidance and policy can be shaped by multiple parts of government. A Congress with more vaccine-supportive members could conduct oversight, legislate and influence funding, but Grossman and Miller argue that it may not by itself reverse or prevent decisions made by federal agencies or state governments.
The authors’ argument centers on the balance of power. They say President Donald Trump has supported a theory of broad presidential authority over the executive branch, while Health and Human Services Secretary Robert F. Kennedy Jr. has a long-standing record of opposing vaccine policies. The article predicts that this combination could leave vaccine policy exposed even if the midterms shift congressional representation. That is the writers’ interpretation of future risks, rather than confirmation that specific actions will follow.
For readers, the practical point is that election results may not settle disputes over vaccine recommendations, school requirements or the role of federal health agencies. Those questions could continue through agency decisions, legislation, state action and court cases.
As an affiliate, we earn on qualifying purchases.
Advocacy Gains and 2026 Setbacks
The authors describe 2026 as a mixed year for vaccine advocacy. They credit coalitions with coordinating opposition to federal and state measures, but say vaccine policy did not become as prominent a national election issue as advocates had hoped. They cite competing public concerns, including two wars that they say pushed up food and energy prices, a mild 2025–26 flu season and a muted federal response to measles outbreaks.
Grossman and Miller also say vaccine policy debates became more fragmented and locally focused. They write that Kennedy temporarily pursued less direct policies after controversy over ACIP, while continuing to advance his broader agenda. They cite increased vaccine-injury research at the National Institutes of Health as one area of focus. These descriptions and interpretations are presented by the authors; the article does not set out a full inventory of policy actions or independently assess their effects.
“Even an outcome that brings more pro-vaccine members to Congress will still leave vaccines facing long-term existential threats at both the federal and state levels.”
— Steven Grossman and Michael Miller, writing in MedPage Today
As an affiliate, we earn on qualifying purchases.
Election Results and Policy Moves Remain Open
As of the article’s publication, the 2026 election outcomes were not yet known. The authors’ projections about control of the House and Senate are not results, and the article does not identify which specific vaccine policies the administration might pursue in 2027.
It is also unclear whether Congress would take up legislation or oversight measures, how the administration would respond, and what courts might decide in pending or future disputes. The authors anticipate more executive action and possible efforts to revive blocked policies, but those are expectations rather than confirmed plans. The article likewise does not establish how individual states will change vaccine rules or how any such changes would affect uptake.
As an affiliate, we earn on qualifying purchases.
The New Congress Convene in January
The next key milestone is the new Congress’s scheduled opening on January 3, 2027, after the midterm election results determine its membership. Lawmakers’ actions, including any oversight, legislation or funding decisions related to public health, will show how far a stronger pro-vaccine bloc can influence policy.
Grossman and Miller expect vaccine advocates to continue organizing against federal and state measures, and they predict the administration may pursue additional policies after the election. Those developments remain to be seen. Readers should watch for official agency decisions, state legislation, court rulings and the final election results; the opinion article does not specify a confirmed policy deadline or next agency announcement.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is the main argument of the article?
Grossman and Miller argue that more vaccine-supportive members of Congress may not be enough to prevent federal and state challenges to vaccine policy after the 2026 midterms.
Have the 2026 midterm results been confirmed in the article?
No. The October 20 article describes election outcomes as forecasts. It says Democratic control of the House is near certain and the Senate is a roughly even prospect, but reports no final results.
What vaccine policy disputes do the authors cite?
They cite changes to ACIP and routine vaccine recommendations, shifts involving federal vaccine advisory groups and respiratory vaccine guidance, and state initiatives to expand school vaccine exemptions. The article also refers to a legal challenge over ACIP changes without giving its outcome.
What happens next?
The new Congress is scheduled to convene on January 3, 2027. Its response, along with agency decisions, state actions and court rulings, will help show whether congressional support changes the policy outlook. The authors’ predictions about future administration actions remain unconfirmed.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
